Does BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. sponsor H-1B?
Yes. BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. filed H-1B LCAs covering 9 positions in fiscal year 2026.
BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. filed E-3 LCAs covering 1 position in fiscal year 2022.
ICE employer reports show F-1 student hires at BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. in 2024:
- CPT Students
- 112
Hiring Trends
H-1B Salary Data
| Visa type | New Hires | Min | P25 | Median salary | P75 | Max |
|---|---|---|---|---|---|---|
| H-1B | 2 | $170,000 | $173,750 | $177,500 | $181,250 | $185,000 |
Job Titles
| Job Title Filed↕ | SOC↕ | Positions↓ | Median↕ | Mean↕ |
|---|---|---|---|---|
| Associate Director, Principal Clinical Data Scientist | 15-2041.01 · Biostatisticians | 2 | $173k | $173k |
| Principal Clinical Data Scientist | 15-2041.01 · Biostatisticians | 1 | $166k | $166k |
| Principal Clinical Data Scientist | 15-2051.00 · Data Scientist | 1 | $176k | $176k |
| Senior Clinical Data Scientist | 15-2041.01 · Biostatisticians | 1 | $146k | $146k |
| Senior Clinical Data Scientist | 15-2051.00 · Data Scientist | 1 | $158k | $158k |
| SENIOR CLINICAL DATA SCIENTIST | 15-2041.01 · Biostatisticians | 1 | $158k | $158k |
| Associate Director, Business Analytics TA | 15-2051.00 · Data Scientist | 1 | $185k | $185k |
| Trial Clinical Pharmacologist | 19-1042.00 · Medical Scientists, Except Epidemiologists and Advisors | 1 | $142k | $142k |
H-1B Filings
Work Locations
| City | State | LCA filings |
|---|---|---|
| Ridgefield | CT | 9 |
F-1 Hiring
| Year | OPT Students | STEM OPT Students | CPT Students |
|---|---|---|---|
| 2018 | -- | -- | 41 |
| 2024 | -- | -- | 112 |
OPT, STEM OPT, and CPT figures come from ICE's annual employer report, which is not published every year, so some years may be blank.
Data Sources
- The Department of Labor releases LCA disclosure data quarterly. Figures on this page reflect filings through FY2026 Q2.
- ICE provides OPT, STEM OPT, and CPT employer data once a year, and not every year has been released. The most recent report covers 2024.